Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0

TLDR

Brain PET imaging is increasingly used to supplement MRI in glioma management, and its application should be considered within local conditions and regulations. These guidelines aim to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting brain PET imaging with FDG and amino‑acid tracers MET, FET, and FDOPA, thereby promoting appropriate use and evidence‑based practice to improve diagnostic impact. The standards were jointly developed by the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, the European Association of Neurooncology, and the PET‑RANO working group. The current document replaces the 2006 guidelines and supplements recent evidence‑based recommendations on PET imaging in glioma patients. References include Vander Borght et.

Abstract

These joint practice guidelines, or procedure standards, were developed collaboratively by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the working group for Response Assessment in Neurooncology with PET (PET-RANO). Brain PET imaging is being increasingly used to supplement MRI in the clinical management of glioma. The aim of these standards/guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with glioma to achieve a high-quality imaging standard for PET using FDG and the radiolabelled amino acids MET, FET and FDOPA. This will help promote the appropriate use of PET imaging and contribute to evidence-based medicine that may improve the diagnostic impact of this technique in neurooncological practice. The present document replaces a former version of the guidelines published in 2006 (Vander Borght et al. Eur J Nucl Med Mol Imaging. 33:1374–80, 2006), and supplements a recent evidence-based recommendation by the PET-RANO working group and EANO on the clinical use of PET imaging in patients with glioma (Albert et al. Neuro Oncol. 18:1199–208, 2016). The information provided should be taken in the context of local conditions and regulations.